Summary & Overview
HCPCS Q9998: Ustekinumab-aekn (Selarsdi) biosimilar injection, 1 mg
HCPCS Level II code Q9998 designates the biosimilar formulation of ustekinumab marketed as Selarsdi, billed per 1 mg of product. As a biosimilar billing code for a high-cost biologic, Q9998 matters nationally for drug reimbursement, patient access to biologic therapies, and payer coverage policy development. It affects hospital outpatient departments, infusion centers, and physician practices that administer or procure biologic therapies.
Key payers included in the coverage discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, how it is used in clinical settings, and the typical sites of service. The publication also provides benchmarking context, common billing considerations, and recent policy developments relevant to biosimilar adoption and reimbursement for infused or injected biologics.
The report is intended to help billing managers, revenue cycle leaders, and policy analysts understand where Q9998 fits within pharmacy and medical benefits, what to expect in payer interactions, and which operational areas (procurement, infusion scheduling, claims submission) are most affected. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q9998 represents an injection of ustekinumab-aekn (Selarsdi), biosimilar, dosed as 1 mg. This code is used to bill for the biologic agent itself when administered as part of patient care.
Service type: Drug administration – biologic/biosimilar product
Typical site of service: Infusion center, outpatient clinic, or physician office
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical adult patient with moderate-to-severe plaque psoriasis or Crohn disease presents to an outpatient infusion or injection clinic for administration of a subcutaneous biologic biosimilar. The medication administered is Q9998 — ustekinumab-aekn (Selarsdi) — billed per 1 mg. The clinical workflow begins with nurse verification of patient identity, allergy check, and review of recent weight and medication reconciliation. Baseline disease activity, prior biologic response, and infection risk screen (including tuberculosis and hepatitis testing as indicated) are confirmed by the prescribing clinician prior to each maintenance or induction dose. The pharmacist prepares the dose according to the ordered mg amount; for billing, the clinic documents milligrams administered and uses Q9998 units equivalent to the mg supplied. The nurse performs the subcutaneous injection at a typical outpatient clinic, physician office, ambulatory infusion center, or specialty biologics clinic; observation for immediate hypersensitivity reactions follows per facility protocol. Documentation includes diagnosis linkage, lot and expiration numbers, amount administered (mg), site of injection, and any modifier required to denote unusual circumstances (for example, billed with modifier 52 for reduced services when a partial dose is given). Payors commonly billed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for outpatient biologic administration and drug acquisition reimbursement.
Coding Specifications
| Modifier | Description | When to Use |
|---|